ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy®—the first and only approved needle-free adrenaline-based product—over traditional adrenaline auto-injectors.i,ii The late-breaking data, presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, United States, suggest EURneffy® has the potential to address persistent practical and psychological barriers that limit consistent auto-injector availability and usage, leaving many patients without life-saving medication when they need it most. Research shows that approximately half of those living with a severe allergy did not administer their auto-injector when needed in an emergencyiii...

Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant in South Korea met both primary and secondary efficacy endpoints of subjective total sleep time (sTST), subjective latency to sleep onset (sLSO) and subjective wake after sleep onset (sWASO)Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for daridorexant, a dual orexin receptor antagonist, for the treatment of adult patients with insomnia. This submission follows positive data from the Phase 3 trial of daridorexant in South...

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I/IIa clinical trial of HMPL-A580, HUTCHMED’s second novel Antibody-Targeted Therapy Conjugate (“ATTC”), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient received the first dose on March 4, 2026. HMPL-A580 is a first-in-class ATTC comprising a highly selective and potent PI3K/PIKK small-molecule inhibitor payload linked to an anti-EGFR antibody via a cleavable linker, HUTCHMED’s second ATTC based on this highly novel PI3K/PIKK...

– Earnings Call Scheduled for 8:00 AM ET on March 24, 2026 – SHANGHAI, China, March 04, 2026 (GLOBE NEWSWIRE) — Hesai Group (“Hesai,” “Hesai Technology” or the “Company”) (NASDAQ: HSAI; HKEX: 2525), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced that it will report its fourth quarter and full year 2025 unaudited financial results on Tuesday, March 24, 2026, before the U.S. market opens. The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 24, 2026 (8:00 PM Beijing/Hong Kong Time on March 24, 2026). For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration and dial in 5 minutes prior to the scheduled call start time. Upon registration, each participant...

With over 450,000 sqm and 4,000 employees, GXO’s Polish operations are its largest in Central Europe GXO celebrated the opening of its new Central Europe headquarters in Warsaw honoring dozens of colleagues who have been with the company for more than 18 years Poland is currently the fifth-largest logistics and warehouse market in Europe and the third largest in terms of demand, confirming its role as a key logistics hub in the region WARSAW, Poland, March 04, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today marked 20 years of transforming the logistics landscape in Poland, the fifth-largest logistics market in Europe. Over two decades, GXO has become synonymous with innovation and operational excellence in the region, leveraging advanced automation and deep...

REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration To participate in the Q&A, register here: Q4 and Full Year 2025 conference call registrationSlides and other material will be made available on https://investors.alvotech.com/news-events/events before the call. For further information,...

REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration To participate in the Q&A, register here: Q4 and Full Year 2025 conference call registrationSlides and other material will be made available on Events and Presentations before the call. For further information, contact: MediaBenedikt StefanssonSarah MacLeodalvotech.media@alvotech.com InvestorsDr....

INVL Baltic Real Estate (hereinafter – the “Company”) informs that on 3 March 2026 it signed an agreement with AB Artea bank (hereinafter – the “Bank”) regarding an amendment to the existing credit agreement. Under the signed agreement, the maximum credit amount has been increased to EUR 23.1 million. Pursuant to this agreement, the Company is granted an additional credit facility of up to EUR 8 million. The final maturity date of the credit has also been extended from 27 June 2028 to 2 March 2031. Following the increase of the credit limit, the Bank’s loan-to-investment ratio will increase from 35% to approximately 55%. The additional financing will be used for the capital renovation of the building located at A. Stulginskio g. 8, Vilnius, as well as for other financial obligations related to the Company’s operations. Following...

Availability of a short formof the 2025 Annual Financial Report A short form of the Dassault Aviation 2025 Annual Financial Report (version abrégée du Rapport Financier Annuel 2025) is available to the public, awaiting the issuance of the statutory auditors’ reports. This short form of the 2025 Annual Financial Report can be found on the company’s website at www.dassault-aviation.com, in the “Finance / Publications / 2026 Publications” section. The full 2025 Annual Financial Report will be made available to the public and filed with the French Financial Markets Authority (Autorité des Marchés Financiers) later in March 2026. ABOUT DASSAULT AVIATION: With over 10,000 military and civil aircraft (including 2,800 Falcons) delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized...